Since 2006 PolyCrystalLine collaborates with the Molecular Crystal Engineering (MCE) group at the Chemistry Department G. Ciamician of the University of Bologna for a biennal conference: the “CrystalForms@Bo”, now in its twelfth edition. The main objective of the meeting, that will take place in Bologna from September 10 to 12, is that of providing a forum for an open academy-industry discussion of the new challenges …
Continue Reading
In less than a month we will take off to New York and take part to DCAT (Drug, Chemical & Associated Technologies Association) Week, a great opportunity to meet some old friends as well as new potential business partners from all over the world. And of course it will be a chance to enjoy again the City that never sleeps. If you are interested into scheduling a meeting please contact Stefano Luca Giaffreda or Marco …
Continue Reading
Are we going to be present at the next CPhI in Frankfurt? We are, of course! For three days, from November 1st to 3rd, we have the opportunity to reaffirm the identity of the company and meet professionals from many different countries. As if it were not enough, we will introduce our last reason of pride: the brand new PolyCrystalLine …
Continue Reading
ABOUT THE CH@BO n.11 ONLINE CONVENTION Because of the uncertainties still associated with the pandemic of SARS-COVID-19 the 11th edition of the Bologna Convention on Crystal Forms CF@Bo n. 11 will take place in online mode. As in the past occasions the meeting will bring together, albeit in virtual mode, academic and industrial experts interested in sharing experience and discussing …
Continue Reading
New Crystalline Forms of Des-Methyl-Venlafaxine Salt Discovered PolyCrystalLine s.r.l. and Segrub Pharmaceuticals have developed a generic equivalent to Pristiq (desvenlafaxine succinate). This DEP001 product is expected to enter the US market at least three years before any other generic desvenlafaxine products enter the market. Pristiq sales are projected to exceed one billion dollars yearly. Pristiq was approved in 2008 by Wyeth Pharmaceuticals for the treatment …
Continue Reading
ABSTRACT: The structure−property relationships of new polymorphs of the chiral herbicide imazamox were investigated by X-ray diffraction, hot stage microscopy (HSM), and differential scanning calorimetry (DSC). Four different polymorphs of imazamox(R) were found. The relationship between different crystal forms, relative thermal stability, and possible conversions pathways was explored. Racemic imazamox, for which no polymorphic modifications could be observed, was also characterized …
Continue Reading
We invite you to join us at our booth n. 4H93 and learn more about our capabilities: Solid Form Development Crystallization Optimization Analytical Services cGMP Manufacturing – PolyCrystalLine CDMO In order to schedule a meeting please contact marco.glucini@polycrystalline.it
Continue Reading
We invite you to join us in our meeting room at the Intercontinental Suite #510/511 and learn more about our capabilities: Solid Form Development Crystallization Optimization Analytical Services In order to schedule a meeting please contact luca.covello@polycrystalline.it.
Continue Reading
New Crystalline Forms of Dex-Lansoprazole Discovered PolyCrystalLine s.r.l. and Segrub Pharmaceuticals have developed a generic equivalent to Kapidex (dexlansoprazole). This DEP002 product contains a new and stable crystal of dexlansoprazole which circumvents Takeda’s intellectual property. Kapidex is a proton pump inhibitor that obtained FDA approval in 2009 by Takeda Pharmaceuticals for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease …
Continue Reading
PolyCrystalLine discovered a novel crystalline form of Minodronic Acid and filed a patent application. For additional information contact info@polycrystalline.it
Continue Reading